Kangmei Pharma | 600518 - Ebitda


Kangmei Pharma reported CNY-12.72M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Avita Medical AUD -9.69M 12.21M Dec/2025
Cspc Pharmaceutical CNY 2.19B 21.88M Dec/2024
Dianthus Therapeutics USD -46.46M 6.27M Mar/2026
Genomma Lab Internacional MXN 944.9M 31.44M Sep/2026
Hypermarcas BRL 642.42M 86.79M Mar/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
IQVIA Holdings USD 1.03B 38M Sep/2026
Jiangsu Hengrui CNY 2.4B 159.2M Jun/2026
Kangmei Pharma CNY -12.72M 30.02M Mar/2026
Moderna USD -1.26B 468M Mar/2026
Organon & Co USD 371M 44M Jun/2026
Revvity USD 228.18M 44.73M Jun/2026
Sh Fosun Pharma CNY 1.65B 88.09M Mar/2026
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Viatris USD 1.19B 138.8M Jun/2026
WuXi AppTec CNY 7.98B 2.34B Jun/2026
Xeris Pharmaceuticals USD 12.33M 12.76M Mar/2026
Zhangzhou Pientzehuang Pharmaceutical CNY 882.7M 351.1M Mar/2026